Investors
24 million
patients were treated with Roche medicines in 2024
30 billion
Roche Diagnostics test were delivered to customers worldwide in 2024
+1%
Core investments in research and development in 2024: CHF 13.2 billion
Our two divisions are focusing jointly on three disease areas that will account for almost 50% of the global disease burden by 2035: cancer, cardiovascular-metabolic diseases and neurological diseases.
Investor updates
Upcoming Investor events
View all eventsLatest reports
Investor relations team contacts
Do you need to get in touch with us? Reach out to our investor relations team with your enquiries.